Adicet Bio Inc [ACET] stock is trading at $1.09, up 9.80%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ACET shares have gain 17.76% over the last week, with a monthly amount glided 7.39%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright downgraded its rating to Neutral on September 11, 2024. On June 27, 2023, downgrade downgraded it’s rating to Mkt Perform. Guggenheim downgraded its rating to a Neutral. JP Morgan downgraded its rating to a Neutral and reduced its price target to $6 on June 01, 2023. JP Morgan started tracking with a Overweight rating for this stock on September 21, 2022, and assigned it a price target of $23. In a note dated March 31, 2022, SMBC Nikko initiated an Outperform rating and provided a target price of $28 on this stock.
Adicet Bio Inc [ACET] stock has fluctuated between $0.81 and $3.77 over the past year. Currently, Wall Street analysts expect the stock to reach $32.5 within the next 12 months. Adicet Bio Inc [NASDAQ: ACET] shares were valued at $1.09 at the most recent close of the market. An investor can expect a potential return of 2881.65% based on the average ACET price forecast.
Analyzing the ACET fundamentals
Gross Profit Margin for this corporation currently stands at 0.62% with Operating Profit Margin at -9.96%, Pretax Profit Margin comes in at -9.14%, and Net Profit Margin reading is -9.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.54 and Total Capital is -0.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0040 points at the first support level, and at 0.9180 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1330, and for the 2nd resistance point, it is at 1.1760.
Ratios To Look Out For
For context, Adicet Bio Inc’s Current Ratio is 10.64. Also, the Quick Ratio is 10.64, while the Cash Ratio stands at 5.44.
Transactions by insiders
Recent insider trading involved Kauffman Michael, Director, that happened on Jun 05 ’24 when 5900.0 shares were sold. Director, ORBIMED ADVISORS LLC completed a deal on Jan 25 ’24 to buy 3.12 million shares. Meanwhile, Director GORDON CARL L bought 3.12 million shares on Jan 25 ’24.
